Aspirin Effectiveness Study
Aspirin Effectiveness in Coronary Artery Disease Patients in Ireland
1 other identifier
observational
500
1 country
1
Brief Summary
Aspirin is an effective medicine for prevention of heart attacks in patients with coronary artery disease and works by preventing clots from forming. In previous studies aspirin has been found to be ineffective in between 2% and 65% of patients but none of these studies have looked specifically at coronary artery disease patients in Ireland. This study is being done to identify the percentage of patients in Ireland whose aspirin is not working effectively and help identify factors that could be used to target interventions to increase aspirin's effectiveness in Irish patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2010
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2010
CompletedFirst Submitted
Initial submission to the registry
April 27, 2010
CompletedFirst Posted
Study publicly available on registry
April 29, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2017
CompletedDecember 19, 2016
December 1, 2016
7 years
April 27, 2010
December 16, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of patients with non-response to aspirin
Prevalence of non-response to aspirin in coronary artery disease patients in Ireland by measurement of serum thromboxane B2
Following a minimum of 3 months of daily aspirin use
Study Arms (1)
CAD patients
Representative sample of coronary artery disease patients receiving aspirin therapy for secondary prevention
Eligibility Criteria
Representative sample of coronary artery disease patients in Ireland receiving aspririn therapy for secondary prevention of cardiovascular events
You may qualify if:
- Age 18 years or older
- Patients with documented coronary artery disease
- Current treatment with any dose of aspirin daily for a minimum of 3 months
- Able to provide written informed consent based on competent mental status
You may not qualify if:
- Myocardial infarction, unstable angina or stroke during the preceding three months
- Platelet count \<125,000/mm
- Known haematological disorders
- Active malignancy on current chemotherapy or a recent diagnosis of cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Beaumont Hospital
Dublin, Dublin, Ireland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Prof. Dermot Kenny, MB, BCh, BAO, MD
Royal College of Surgeons, Ireland
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Dermot Kenny
Study Record Dates
First Submitted
April 27, 2010
First Posted
April 29, 2010
Study Start
April 1, 2010
Primary Completion
April 1, 2017
Study Completion
April 1, 2017
Last Updated
December 19, 2016
Record last verified: 2016-12